199 related articles for article (PubMed ID: 22998742)
1. An exploratory study of combination buspirone and melatonin SR in major depressive disorder (MDD): a possible role for neurogenesis in drug discovery.
Fava M; Targum SD; Nierenberg AA; Bleicher LS; Carter TA; Wedel PC; Hen R; Gage FH; Barlow C
J Psychiatr Res; 2012 Dec; 46(12):1553-63. PubMed ID: 22998742
[TBL] [Abstract][Full Text] [Related]
2. Changes in cognitive symptoms after a buspirone-melatonin combination treatment for Major Depressive Disorder.
Targum SD; Wedel PC; Fava M
J Psychiatr Res; 2015 Sep; 68():392-6. PubMed ID: 26025562
[TBL] [Abstract][Full Text] [Related]
3. A randomized double-blind placebo-controlled trial of treatment as usual plus exogenous slow-release melatonin (6 mg) or placebo for sleep disturbance and depressed mood.
Serfaty MA; Osborne D; Buszewicz MJ; Blizard R; Raven PW
Int Clin Psychopharmacol; 2010 May; 25(3):132-42. PubMed ID: 20195158
[TBL] [Abstract][Full Text] [Related]
4. Melatonin synergizes with citalopram to induce antidepressant-like behavior and to promote hippocampal neurogenesis in adult mice.
Ramírez-Rodríguez G; Vega-Rivera NM; Oikawa-Sala J; Gómez-Sánchez A; Ortiz-López L; Estrada-Camarena E
J Pineal Res; 2014 May; 56(4):450-61. PubMed ID: 24650119
[TBL] [Abstract][Full Text] [Related]
5. Use of slow-release melatonin in treatment-resistant depression.
Dalton EJ; Rotondi D; Levitan RD; Kennedy SH; Brown GM
J Psychiatry Neurosci; 2000 Jan; 25(1):48-52. PubMed ID: 10721684
[TBL] [Abstract][Full Text] [Related]
6. Exploratory analyses of efficacy data from major depressive disorder trials submitted to the US Food and Drug Administration in support of new drug applications.
Khin NA; Chen YF; Yang Y; Yang P; Laughren TP
J Clin Psychiatry; 2011 Apr; 72(4):464-72. PubMed ID: 21527123
[TBL] [Abstract][Full Text] [Related]
7. Possible augmentation of antidepressant response by buspirone.
Jacobsen FM
J Clin Psychiatry; 1991 May; 52(5):217-20. PubMed ID: 2033029
[TBL] [Abstract][Full Text] [Related]
8. A comparative analysis between site-based and centralized ratings and patient self-ratings in a clinical trial of Major Depressive Disorder.
Targum SD; Wedel PC; Robinson J; Daniel DG; Busner J; Bleicher LS; Rauh P; Barlow C
J Psychiatr Res; 2013 Jul; 47(7):944-54. PubMed ID: 23562150
[TBL] [Abstract][Full Text] [Related]
9. The efficacy profile of vilazodone, a novel antidepressant for the treatment of major depressive disorder.
Reed CR; Kajdasz DK; Whalen H; Athanasiou MC; Gallipoli S; Thase ME
Curr Med Res Opin; 2012 Jan; 28(1):27-39. PubMed ID: 22106941
[TBL] [Abstract][Full Text] [Related]
10. Does the presence of an open-label antidepressant treatment period influence study outcome in clinical trials examining augmentation/combination strategies in treatment partial responders/nonresponders with major depressive disorder?
Iovieno N; Papakostas GI
J Clin Psychiatry; 2012 May; 73(5):676-83. PubMed ID: 22569112
[TBL] [Abstract][Full Text] [Related]
11. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
Freeman MP; Mischoulon D; Tedeschini E; Goodness T; Cohen LS; Fava M; Papakostas GI
J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327
[TBL] [Abstract][Full Text] [Related]
12. Desvenlafaxine 50 and 100 mg/d in the treatment of major depressive disorder: an 8-week, phase III, multicenter, randomized, double-blind, placebo-controlled, parallel-group trial and a post hoc pooled analysis of three studies.
Tourian KA; Padmanabhan SK; Groark J; Brisard C; Farrington D
Clin Ther; 2009 Jun; 31 Pt 1():1405-23. PubMed ID: 19698901
[TBL] [Abstract][Full Text] [Related]
13. A randomized, double-blind, placebo-controlled trial of augmentation with an extended release formulation of methylphenidate in outpatients with treatment-resistant depression.
Patkar AA; Masand PS; Pae CU; Peindl K; Hooper-Wood C; Mannelli P; Ciccone P
J Clin Psychopharmacol; 2006 Dec; 26(6):653-6. PubMed ID: 17110825
[TBL] [Abstract][Full Text] [Related]
14. An 8-week, randomized controlled trial of atomoxetine, atomoxetine plus buspirone, or placebo in adults with ADHD.
Sutherland SM; Adler LA; Chen C; Smith MD; Feltner DE
J Clin Psychiatry; 2012 Apr; 73(4):445-50. PubMed ID: 22313788
[TBL] [Abstract][Full Text] [Related]
15. Combination therapy of imipramine and melatonin: additive antidepressant effect in mouse forced swimming test.
Ergün Y; Orhan FO; Karaaslan MF
Eur J Pharmacol; 2008 Sep; 591(1-3):159-63. PubMed ID: 18601918
[TBL] [Abstract][Full Text] [Related]
16. Efficacy of extended release quetiapine fumarate monotherapy in patients with major depressive disorder: a pooled analysis of two 6-week, double-blind, placebo-controlled studies.
Weisler RH; Montgomery SA; Earley WR; Szamosi J; Lazarus A
Int Clin Psychopharmacol; 2012 Jan; 27(1):27-39. PubMed ID: 22027845
[TBL] [Abstract][Full Text] [Related]
17. Duloxetine versus escitalopram and placebo: an 8-month, double-blind trial in patients with major depressive disorder.
Pigott TA; Prakash A; Arnold LM; Aaronson ST; Mallinckrodt CH; Wohlreich MM
Curr Med Res Opin; 2007 Jun; 23(6):1303-18. PubMed ID: 17559729
[TBL] [Abstract][Full Text] [Related]
18. Melatonin treatment mimics the antidepressant action in chronic corticosterone-treated mice.
Crupi R; Mazzon E; Marino A; La Spada G; Bramanti P; Cuzzocrea S; Spina E
J Pineal Res; 2010 Sep; 49(2):123-9. PubMed ID: 20536684
[TBL] [Abstract][Full Text] [Related]
19. A double-blind, multicenter trial comparing duloxetine with placebo in the treatment of fibromyalgia patients with or without major depressive disorder.
Arnold LM; Lu Y; Crofford LJ; Wohlreich M; Detke MJ; Iyengar S; Goldstein DJ
Arthritis Rheum; 2004 Sep; 50(9):2974-84. PubMed ID: 15457467
[TBL] [Abstract][Full Text] [Related]
20. The vasopressin V(1b) receptor antagonist SSR149415 in the treatment of major depressive and generalized anxiety disorders: results from 4 randomized, double-blind, placebo-controlled studies.
Griebel G; Beeské S; Stahl SM
J Clin Psychiatry; 2012 Nov; 73(11):1403-11. PubMed ID: 23146246
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
